Status:
UNKNOWN
Validation of an Italian Questionnaire of Adherence to the Ketogenic Diet
Lead Sponsor:
University of Pavia
Collaborating Sponsors:
University of Sao Paulo
Conditions:
Epilepsy
Eligibility:
All Genders
Up to 60 years
Brief Summary
The ketogenic diet (KD) represents an effective and safe non-drug treatment for drug-resistant epilepsy in pediatric and adult age based on normocaloric, hyperlipidic (80-90% of the daily energy), nor...
Detailed Description
The ketogenic diet (KD) represents an effective and safe non-drug treatment for drug-resistant epilepsy in pediatric and adult age and is the gold standard therapy for type I glucose transporter defic...
Eligibility Criteria
Inclusion
- Age \<60 years
- Gender: both sexes
- Route of administration of the diet: totally or partially oral
- Diagnosis: drug-resistant epilepsy or GLUT1 deficiency
- Duration of treatment with the ketogenic diet: at least 3 months
- Informed consent of the patient and / or an authorized caregiver / legal representative•
Exclusion
- Age \> 60 years
- Route of administration of the exclusively enteral or parenteral diet
- Duration of treatment with KD less than 3 months
Key Trial Info
Start Date :
March 16 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
September 1 2022
Estimated Enrollment :
105 Patients enrolled
Trial Details
Trial ID
NCT05377762
Start Date
March 16 2022
End Date
September 1 2022
Last Update
June 22 2022
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Pavia
Pavia, Italy, 27100
2
Center for Childhood and Adolescent Epileptology of the Mondino Foundation
Pavia, Italy